Testing effectiveness (Phase 2)Study completedNCT04492514
What this trial is testing
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Who this might be right for
COVID 19SARS-CoV 2Pneumonia
Kristin Hudock 1